Tests - Protein Binding

The extent of protein binding in the plasma or tissues controls the volume of distribution and affects both hepatic and renal clearance. The volume of distribution (V) depends on the fraction unbound in plasma (/u), the fraction unbound in tissue (/ut), the volume of tissue (Vt), and the volume of plasma (Up) by the equation  

The influences of plasma binding on drug elimination may be best understood by consideration of clearance. All organ clearance models incorporate a proteinbinding term. For example the conversion of the intrin- 

Only the unbound fraction in plasma is filtered in the kidney. Therefore, the rate of filtration is the product of glomerular filtration rate (GFR) and unbound plasma concentration. For a drug which is only filtered and all filtered drug is excreted into the urine, the renal clearance (CLr) is the rate of filtration product  

The binding to plasma or subcellular liver fraction can be taken into account for the prediction of human pharmacokinetic parameters either from preclinical and/or in vitro metabolism data (Obach et al. 1997 Mahmood 2000). Obach (1999) showed by comparison the in vivo investigated clearance values and clearance values projected from in vitro intrinsic clearance data of 29 drugs that the inclusion of blood and liver microsomes binding values gave the best agreement. 

Chapter II.F Distribution - in vitro Tests - Protein Binding 

---

Difference in studies during and after recovery from acute viral hepatitis was significant at P < 0.05 by paired t-test. Protein binding results for individual patients were not given, so was estimated from average values. 

In dye-binding tests, milk is mixed with excess acidic dye solution where the protein binds the dye in a constant ratio and forms a precipitate. After the dye—protein interaction takes place, the mixture is centrifuged and the optical density of the supernatant is determined. Utilization of the dye is thus measured and from it the protein content determined. Several methods for appHcation of dye-binding techniques to milk are given (24,25). 

Sulfaphenazole (684) and sulfazamet (685) are both examples of relatively short acting sulfonamides (B-80MI40406) and their antibacterial activity has been tested against Escherichia coli, the former being more effective than the latter. Sulfaphenazole also displaces sulfonyl ureas from protein binding sites on human serum albumin and consequently increases the concentration of the free (active) drug and produces a more intense reaction that may result in hypoglycemia. 

The three-dimensional strucmres of Cro and of the lambda repressor protein have been determined by x-ray crystallography, and models for their binding and effecting the above-described molecular and genetic events have been proposed and tested. Both bind to DNA using hehx-turn-helix DNA binding domain motifs (see below). 

During the characterization process, hits are typically tested for kinetic solubility and permeability in a model of passive diffusion such as PAMPA [22]. As new compounds are synthesized, additional parameters also need to be considered, such as pZa, chemical and plasma stability, and protein binding. Calculated properties such as MW, clogP, and PSA should also be tracked. 

The overall accuracy of the predictions, assessed as the mean-fold error of prediction of the test set was 2.03, making this approach one that would possess suitable accuracy for use in drug design and human pharmacokinetic predictions. Similar methods developed separately for acids and bases showed an improvement in accuracy. This investigation also included a prediction of unbound VD, which should represent a simpler parameter to predict since it would be based only on tissue binding and not plasma protein binding. However, it is interesting to note that this approach was less accurate for this parameter, which would be unexpected. 

Relationship between the protein-binding of the test compound and the dose levels used. 

The primary objective of integration plot analysis is to analyze the data on influx of the test substrate from the circulating blood to the retina (i.e., blood-to-retina direction) across the BRB after intravenous administration of the test substrate. The advantage of this approach is that it allows reliable determination of the retinal uptake (i.e., clearance) of the test substrate which has a slow permeability across the BRB [28], On the other hand, due to the intravenous injection, interference by endogenous substrates and plasma-protein binding of the test substrate can produce an unseemingly low estimate of the retinal uptake. 

---